Vitamin D status and cholecalciferol supplementation in chronic kidney disease patients: An Italian cohort report by Cupisti, Adamasco et al.
© 2015 Cupisti et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to 
request permission may be found at: http://www.dovepress.com/permissions.php
International Journal of Nephrology and Renovascular Disease 2015:8 151–157
International Journal of Nephrology and Renovascular Disease Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
151
O R I g I N a l  R e s e a R c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/IJNRD.S90968
Vitamin D status and cholecalciferol 
supplementation in chronic kidney disease 
patients: an Italian cohort report
adamasco cupisti
Valentina Vigo
Maria enrica Baronti
claudia D’alessandro
lorenzo ghiadoni
Maria Francesca egidi
Nephrology, Transplant and Dialysis 
Division, aOUP, Department of 
clinical and experimental Medicine, 
University of Pisa, Pisa, Italy
correspondence: adamasco cupisti 
Nephrology, Transplant and Dialysis 
Division, azienda Ospedaliero 
Universitaria Pisana, Department of 
clinical and experimental Medicine, 
University of Pisa, Via Roma 67, 56126 
Pisa, Italy 
Tel +39 050 997291 
email adamasco.cupisti@med.unipi.it
Abstract: This study investigated the factors associated with hypovitaminosis D, in a cohort 
of 405 prevalent patients with chronic kidney disease (CKD) stages 2–4, living in Italy and 
followed-up in tertiary care. The effect of cholecalciferol 10,000 IU once-a-week for 12 months 
was evaluated in a subgroup of 100 consecutive patients with hypovitaminosis D. Vitamin D 
deficiency was observed in 269 patients (66.4%) whereas vitamin D insufficiency was found in 
67 patients (16.5%). In diabetic patients, 25-hydroxyvitamin D deficiency was detected in 80% 
of cases. In patients older than 65 years, the prevalence of hypovitaminosis D was 89%. In the 
univariate analysis, 25-hydroxyvitamin D was negatively related to age, parathyroid hormone 
(PTH), proteinuria, and Charlson index, while a positive relationship has emerged with hemoglo-
bin level. On multiple regression analysis, only age and PTH levels were independently associ-
ated with 25-hydroxyvitamin D levels. No relationship emerged between vitamin D deficiency 
and renal function. Serum levels of 25-hydroxyvitamin D or prevalence of hypovitaminosis D 
did not differ between patients on a free-choice diet and on a renal diet, including low-protein, 
low-phosphorus regimens. Twelve-month oral cholecalciferol administration increased 
25-hydroxyvitamin D and reduced PTH serum levels. In summary, hypovitaminosis D is very 
prevalent in CKD patients (83%) in Italy, and it is similar to other locations. PTH serum levels 
and age, but not renal function, are the major correlates of hypovitaminosis D. Implementation 
of renal diets is not associated with higher risk of vitamin D depletion. Oral cholecalciferol 
administration increased 25-hydroxyvitamin D and mildly reduced PTH serum levels. Oral 
cholecalciferol supplementation should be recommended as a regular practice in CKD patients, 
also when serum 25-hydroxyvitamin D determination is not available or feasible.
Keywords: CKD, vitamin D, cholecalciferol, calcifediol, hypovitaminosis, PTH, renal disease, 
CKD-MBD
Introduction
Disorders of vitamin D metabolism are frequent in chronic kidney disease (CKD) 
and represent a crucial physiopathological mechanism of CKD and mineral bone 
disorders. Vitamin D deficiency is a highly prevalent abnormality in CKD patients,1,2 
as well as the reduction of the active form, calcitriol – 1,25-hydroxyvitamin D. Sun 
exposure is crucial to meet the requirements for vitamin D. Thus, factors such as 
climate, location, aging, lifestyle, and skin pigmentation may affect the endogenous 
production of vitamin D.
However, dietary intake of cholecalciferol (from animal sources) or ergocalciferol (from 
plant sources) plays a role and represents nearly 20% of the 25-hydroxyvitamin D supply. 
It has been suggested that renal diets targeted to reducing dietary phosphorus intake 
International Journal of Nephrology and Renovascular Disease 2015:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
152
cupisti et al
can contribute to the development of hypovitaminosis D in 
CKD patients, especially in dialysis patients.3
Vitamin D deficiency is defined as 25-hydroxyvitamin D 
serum levels lower than 20 ng/mL, whereas vitamin D insuf-
ficiency is defined as 25-hydroxyvitamin D serum levels 
ranging 21–30 ng/mL.4 Vitamin D deficiency causes bone 
and mineral abnormalities and may also play a role in several 
diseases including infection, cardiovascular diseases, malig-
nancy, insulin resistance, diabetes, autoimmune disease, and 
impaired physical functioning.4 In CKD patients, vitamin D 
deficiency is associated with poorer outcomes.5,6
The prevalence of vitamin D insufficiency/deficiency 
status is similar in people without or with CKD who do not 
require dialysis.7 Major determinants of vitamin D status 
include age, sex, body mass index, obesity, and diabetes.8
Instead, the level of residual renal function is not a direct 
major determinant of vitamin D status.7 However, certain 
conditions associated with CKD such as protein losses or 
inadequate food intake can predispose CKD patients to severe 
hypovitaminosis D.
Guidelines recommend to treat hypovitaminosis D 
and suggest an optimal 25-hydroxyvitamin D serum 
levels .30 ng/mL, even if this cutoff is not based on strong 
evidence. In recent years, vitamin D supplementation prac-
tices are increased significantly and have achieved greater 
serum 25-hydroxyvitamin D levels.9,10
In the present study, we examined the prevalence of 
vitamin D deficiency in CKD patients living in our county, 
and the correlates for vitamin D insufficiency/deficiency 
including dietary regimens. The effects of a once-a-week 
cholecalciferol supplementation schedule in vitamin D 
depleted CKD patients have been examined, as well.
Patients and methods
This population-based, prospective study includes CKD 
outpatients, free from dialysis, on tertiary care. Patients 
were included if aged .18 years, if were in stable clinical 
conditions, and if in CKD stages 2–4. Exclusion criteria 
were malignancy, acute illness, hospital admission in the 
previous 3 months, systemic inflammatory diseases, hepatic 
insufficiency, inflammatory bowel disease, pancreatitis, 
hypercalcemia, hyperphoshatemia, and parathyroid hor-
mone (PTH) serum levels .500 pg/mL. Kidney transplant 
recipients or patients taking any vitamin D product (calcitriol, 
calcifediol, paracalcitol, ergocalciferol, and cholecalciferol) 
were excluded as well.
We finally included 405 prevalent outpatients: 260 males 
(age 68.3±12.3 years) and 145 females (age 68.9±13.0 years).
All the patients underwent an assessment for 25- 
hydroxyvitamin D serum levels. PTH, calcium, phosphorus, 
serum albumin, lipid panel as well as serum creatinine, urea, 
electrolytes, uric acid, and hemoglobin were determined 
in overnight fasting blood samples. Body mass index and 
Charlson comorbidity index were calculated as well.
A subgroup of 100 consecutive patients with hypovita-
minosis D (,30 ng/mL), who received oral supplementa-
tion of cholecalciferol (10,000 IU/week) and who were 
evaluated at baseline and after 12 months of treatment, were 
retrospectively selected. The evaluation at 12 months was 
assumed to exclude the bias due to seasonal variability in 
25-hydroxyvitamin D levels.
25-Hydroxyvitamin D serum levels were determined 
using an high performance liquid chromatography-UV 
method (Eureka Lab Division, Chiaravalle, Ancona, Italy). 
Serum 1-84 PTH was measured using a second generation 
assay (Liaison N-tact PTH II, DiaSorin, Saluggia, Italy), in all 
the cases. All the other biochemical analysis was performed 
by routinely used laboratory methods. Glomerular filtration 
rate was estimated (eGFR) by the 4-variable Modification of 
Diet in Renal Disease formula.1 This study was in adherence 
with the Declaration of Helsinki and was approved by the 
Ethics Committee of the Institutional Review Board at Pisa 
University Hospital.
statistical analysis
Descriptive statistics is given as mean ± standard deviation. 
Statistical analysis was performed by Student’s t-test for 
unpaired and paired samples.
Simple and multiple regression analyses were performed 
to examine univariate and independent correlations of 
25-hydroxyvitamin D serum levels.
Differences were considered as statistically significant 
when P,0.05.
Results
Table 1 shows the demographic and laboratory characteristics 
of the entire cohort of patients, according to CKD stages.
As a whole, 25-hydroxyvitamin D serum levels resulted 
17.5±11.2 ng/mL. No differences were observed between 
males and females (18.2±11.0 and 16.4±11.6 ng/mL, 
respectively). Vitamin D deficiency was observed in 
269 patients (66.4%), whereas vitamin D insufficiency was 
found in 67 patients (16.5%). Hence a cumulative detection 
of hypovitaminosis D was observed in 82.9% of our CKD 
population. Figure 1 shows the prevalence of vitamin D 
deficiency and insufficiency by tertiles of age. In the second 
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Table 1 Demographic and laboratory characteristics of the entire cohort of studied patients, according to cKD stages
CKD stage (n)  
4 (70)
CKD stage (n)  
3b (158)
CKD stage (n)  
3a (111)
CKD stage (n) 
2 (65)
age, years 71±11.8 70.7±12.1 68.7±11.2 60.5±13.6
25(Oh)D, ng/ml 16.1±10.9 16±10.3 19.1±12.7 20.2±11.6
iPTh, pg/ml 174±128 108±63 82.2±50.3 70.4±48.3
serum calcium, mg/dl 9.4±0.5 9.4±0.5 9.4±0.9 9.5±0.8
serum phosphate, mg/dl 3.6±0.5 3.3±0.6 3.2±0.6 3.0±0.6
serum urea, mg/dl 93.4±31.5 73±20.2 54.8±16 42±14.1
serum creatinine, mg/dl 2.3±0.5 1.8±0.3 1.4±0.2 1.1±0.2
egFR, ml/min/ 1.73 m2 23.4±3.9 37±4.4 51.7±6.6 70.3±11.1
Urine urea, g/day 15.6±4 19.2±5.4 21±6.6 21.6±6.5
nPcR, g/kg/day 0.8±0.1 0.9±0.2 1.0±0.3 1.0±0.3
Urine creatinine, mg/day 1,034±303 1,233±384 1,269±423 1,359±404
creatinine clearance, ml/min 27.7±7.3 46.7±12.3 66±17.4 89.6±23
serum uric acid, mg/dl 8.9±17.1 6.3±1.5 6.4±1.5 5.7±1.5
serum bicarbonate, mmol/l 24±4.4 25.4±3.1 26.2±3.7 27.7±3.8
Total cholesterol, mg/dl 183±40.7 178±37.6 189±47.9 197±47.7
hDl cholesterol, mg/dl 54.8±32.7 50.2±16 51.6±16.3 58±17.3
lDl cholesterol, mg/dl 100±37.4 101±33.4 111±34.7 115±34.4
Triglycerides, mg/dl 144±83.3 142±74.1 142±66.5 124±70
serum protein, g/dl 7.2±0.6 7.2±0.5 7.2±0.8 7.1±0.8
serum albumin, g/dl 4.1±0.3 4.1±0.3 4.1±0.5 4.2±0.5
hemoglobin, g/dl 12±1.3 13±1.9 13.8±2.2 14.4±1.9
hematocrit, % 37±3.9 39.7±5.3 41.4±6.2 43±5.4
Urine sodium, mmol/day 136±34.1 123±54.1 149±57.5 153±59.5
Body weight, kg 74.3±14.5 77.8±13.4 79.6±14.3 73.6±14
height, m 1.66±0.1 1.67±0.1 1.69±0.2 1.68±0.2
Body mass index, kg/m2 27±6.2 28.2±4.5 28.1±4.4 25.9±4.4
systolic BP, mmhg 137±15.4 141±16.9 136±19.8 135±19.8
Diastolic BP, mmhg 77.7±10.1 78.5±10.3 79.2±12.3 78.6±11.8
Pulse BP, mmhg 59.3±13.3 61.7±16.6 56.7±14.7 56.6±14.5
Note: Data are presented as mean ± standard deviation. 
Abbreviations: BP, blood pressure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HDL, high density lipoprotein; iPTH, intact parathyroid 
hormone; lDl, high density lipoprotein; 25(Oh)D, 25-hydroxyvitamin D; nPcR, normalized protein catabolic rate.
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and third tertiles, the prevalence of hypovitaminosis was 
significantly higher than that in the first tertile. It derives 
that CKD patients older than 65 years have a 90% risk of 
hypovitaminosis D.
As expected, 25-hydroxyvitamin D serum levels were 
higher when blood collection was taken in summer period 
(Figure 2).
Table 2 shows the characteristics of the studied patients, 
according to the 25-hydroxyvitamin D serum levels.
The 25-hydroxyvitamin D levels were lower in diabetic 
than in nondiabetic patients (13.6±9.5 vs 19.4±11.5 ng/mL, 
P,0.001): accordingly, the prevalence of 25-hydroxyvitamin 
D deficiency was higher among the 129 diabetic patients than 
in the nondiabetic cohort (79.8% vs 60.5%, P,0.01).
A total of 225 patients underwent renal dietician 
counseling and were on renal diets consisting of pro-
tein- (,0.8 g/kg/day) and phosphate-restricted regimens, 
which supply quite low amount of vitamin D (median 
0.36 µg/day, range 0.1–0.6 µg/day); 180 patients were 
not on a dietary counseling program and followed a free-
choice diet that presumably contained higher amount of 
VitD normal
VitD insufficiency
VitD deficiency
Tertile 1
0
10
20
30
40
50
60
70
80
90
100
Tertile 2 Tertile 3
Figure 1 Prevalence of vitamin D (VitD) deficiency and insufficiency by tertiles of age.
Notes: Tertile 1: 54.3±10.2 (23–65) years; tertile 2: 70.8±3.0 (66–75) years; tertile 3: 
80.4±3.4 (76–89) years.
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Figure 2 Bimonthly course of the median values of 25-hydroxyvitamin D serum 
levels in the studied cohort.
Table 2 characteristics of the studied patients, according to the 
25(Oh)D serum levels
25-Hydroxyvitamin D 
(ng/mL)
,20 20–29 $30
age, years 70.1±11.8 68.9±11.2 61.7±14.4
25(Oh)D, ng/ml 11±4.6 24.1±2.6 37.4±6.8
iPTh, pg/ml 121.5±87.7 84.4±52.5 68±50.8
serum calcium, mg/dl 9.4±0.5 9.5±0.5 9.5±0.5
serum phosphate, mg/dl 3.3±0.6 3.2±0.6 3.1±0.6
serum urea, mg/dl 70±26.4 62±21.6 58±26
serum creatinine, mg/dl 1.7±0.6 1.6±0.6 1.6±0.5
egFR, ml/min/1.73 m2 42.3±15.1 46.8±16.2 48.8±16.3
creatinine clearance, ml/min 51.7±23.3 57±23.5 70±27.8
Urine creatinine, mg/day 1,162±370 1,262±376 1,385±430
Urine sodium, mmol/day 140±55.2 119±34.3 150±60.7
Urine urea, g/day 19±6 19.1±5.5 21.2±6.4
nPcR, g/kg/day 0.9±0.2 0.9±0.2 1.0±0.3
serum bicarbonate, mmol/l 25.5±3.5 26.4±3.7 25.5±2.8
Uric acid, mg/dl 7±8.9 5.8±1.4 6.4±1.2
cholesterol, mg/dl 186±45.4 182±34.5 183±37.4
hDl cholesterol, mg/dl 51.3±18.3 55±26.6 54.3±13.2
lDl cholesterol, mg/dl 104±35.5 110±31.4 108±33.1
Triglycerides, mg/dl 149±79.1 116.4±56 130±62.2
serum protein, g/dl 7.1±0.5 7.1±0.4 7.3±0.5
serum albumin, g/dl 4.1±0.4 4.2±0.4 4.2±0.3
hemoglobin, g/dl 13±1.8 13.3±1.7 14±1.9
hematocrit, % 39.6±5.1 40.1±4.9 42.1±5.3
Weight, kg 77.5±14 75.9±12.9 76.4±12.7
height, m 1.67±0.1 1.68±0.1 1.69±0.2
BMI, kg/m2 27.9±5.1 26.9±3.5 26.6±3.3
systolic BP, mmhg 139±17.5 138±16.7 133±15.3
Diastolic BP, mmhg 78.6±10.6 78.6±10.2 78.6±10.4
Pulse BP, mmhg 60±15.5 59.6±15.6 54.1±13.1
Abbreviations: BMI, body mass index; BP, blood pressure; egFR, estimated 
glomerular filtration rate; HDL, high density lipoprotein; iPTH, intact parathyroid 
hormone; lDl, high density lipoprotein; 25(Oh)D, 25-hydroxyvitamin D; nPcR, 
normalized protein catabolic rate.
Table 3 simple regression analyses examining univariate and 
independent correlations of 25-hydroxyvitamin D serum levels
Independent  
variable
Regression 
coefficient
Error 
standard
Probability 
level
Intercept 20.741 7.381 0.005
age, years -0.120 0.051 0.019
hb, g/dl 0.769 0.395 0.053
PTh, pg/ml -0.032 0.009 0.001
serum urea, mg/dl -0.027 0.027 0.328
Abbreviations: hb, hemoglobulin; PTh, parathyroid hormone.
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 vitamin D (median 1.3 µg/day, range 0.3–4.0 µg/day). 
Serum 25-hydroxyvitamin D did not differ between these 
two groups (16.5±10.2 vs 18.2±11.8 ng/mL, respectively), 
and no relationship emerged between urinary urea excretion 
and 25-hydroxyvitamin D levels. Within the group of renal 
diet patients, no difference in serum 25-hydroxyvitamin D 
levels resulted between patients (n=55) on a low-protein diet 
(0.6 g/kg/day) and those (n=170) on a protein prescription of 
0.8 g/kg/day (17.1±9.8 vs 16.9±10.5 ng/mL, respectively); 
therefore, no difference emerged regarding the prevalence 
of hypovitaminosis D (65% vs 73%, respectively).
The univariate analysis showed an inverse relationship 
between 25-hydroxyvitamin D levels and age (r=-0.259, 
P,0.001), PTH (r=-0.312, P,0.001), Charlson index 
(r=-0.236, P,0.001), whereas a positive relationship 
with hemoglobin (r=0.210, P,0.001). In the cohort of 
76 patients with urine protein excretion .0.3 g/day, 25- 
hydroxyvitamin D serum levels were inversely related to 
urine protein excretion (r=-0.315, P,0.05).
On multiple regression analysis, only age (R2=0.014) and 
PTH levels (R2=0.060) were independently associated with 
25-hydroxyvitamin D levels (R2=0.15) (Table 3).
In the 100 CKD patients receiving oral supplementation 
of cholecalciferol (10,000 IU/week), we observed a twofold 
increase in 25-hydroxyvitamin D serum levels (Table 4) and 
the prevalence of 25-hydroxyvitamin D deficiency lowered 
from 76% to 33% of patients. A mild but significant reduc-
tion of PTH level occurred despite a mild reduction of eGFR. 
Although serum 25-hydroxyvitamin D nearly doubled in all 
the CKD stages, a significant reduction of PTH occurred in 
stage 3b patients (139±66 vs 117±57 pg/mL, P,0.05) only. 
No changes regarding calcium and phosphorus serum levels 
were observed (Table 4).
Discussion
The present study conf irms the high prevalence of 
25-hydroxyvitamin D depletion in a cohort of CKD patients 
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living in a temperate climate, namely Tuscany (Italy). These 
data are well in agreement with others from different regions 
and reported in the paper by Cuppari and Garcia-Lopes.11 
In most of the published reports, 25-hydroxyvitamin D 
serum levels were lower than 20 ng/mL, so the prevalence 
of 25-hydroxyvitamin D deficiency or insufficiency ranged 
from 70% to nearly 100%.11 A significantly higher average 
level of 25-hydroxyvitamin D has been reported in CKD 
patients living in southern Italy: this is well in accordance 
with the more sunny climate of Sicily than Tuscany.5
Patients older than 65 years showed a very high prevalence 
of hypovitaminosis D, approaching 90%. Hypovitaminosis D 
was also associated with higher Charlson comorbidity index, 
a finding that is in keeping with the well-known relationship 
between hypovitaminosis D and morbidity/mortality risk.
As already reported, hypovitaminosis D was independent 
from the different stages of CKD. At variance with the literature, 
we did not find a higher risk of hypovitaminosis D in women.
A negative relationship emerged between 25- 
hydroxyvitamin D and urine protein excretion. Moreover, 
proteinuric patients can develop vitamin D deficiency by 
urinary loss of vitamin D-binding protein, which binds most 
of the serum calcifediol.
A very high prevalence of vitamin D deficiency was 
observed in diabetic CKD patients. This is of a real concern 
since hypovitaminosis D was associated with an increased 
risk of kidney disease progression and mortality.12,13
In our series, we found a relationship between 
hematocrit or hemoglobin and 25-hydroxyvitamin D. 
These findings are in agreement with other authors who 
reported that in the early CKD 25-hydroxyvitamin D and 
1,25-hydroxyvitamin D deficiencies were independently 
associated with low hemoglobin levels.14 However, the 
reasons accounting for this relationship are not yet known, 
as it is not proven the favorable effect of vitamin D supple-
mentation in improving anemia in CKD patients.15
Renal diets consist of low-protein, low-phosphate regi-
mens including avoidance of dairy products and yolk (for 
the very high phosphate content) and limitation of meat 
and fish. Hence these diets supply lower amount of vita-
min D than mixed free-choice diets. Nevertheless, we did 
not find any association between renal diet regimens and 
25-hydroxyvitamin D deficiency. Namely, the prevalence of 
hypovitaminosis D or 25-hydroxyvitamin D serum levels did 
not differ between patients on low-protein, low-phosphorus 
diets16,17 and those on free-choice diets. This is not surpris-
ing, since dietary supply represents a minor component for 
determining vitamin D status.
The 25-hydroxyvitamin D serum levels were higher when 
blood collection was taken in summer, to confirm the seasonal 
variability of calcifediol (Figure 1). This is also the reason 
why the effect of cholecalciferol administration was assessed 
at 12 months and not at 3 or 6 months.
Multivariate analysis showed that age and PTH explained 
1.5% and 4.5%, respectively, of 25-hydroxyvitamin D 
variance. It is noteworthy that the maximum linearity occurs 
in stage 3b CKD patients.
Evidence exists that not only the reduction of calcitriol, 
but also lower levels of calcifediol can contribute to the 
development of secondary hyperparathyroidism. Therefore, 
vitamin D repletion using ergocalciferol or cholecalciferol is 
recommended to obtain adequate vitamin D status in CKD.11 
K-DIGO guidelines suggest that vitamin D deficiency and 
insufficiency in patients with CKD stages 3–5D should be 
corrected as it occurs in the general population. However, 
this recommendation is based on low quality of evidence 
(2c stage).3
Then, supplementation of cholecalciferol we proposed 
was addressed to patients with hypovitaminosis D and the 
effects were measured at 12-month follow-up, to avoid the 
changes linked to the potential changes of lifestyle and sun 
exposure related to seasonal-climate changes. In our treated 
patients, serum levels of 25-hydroxyvitamin D almost 
doubled, together with a mild decrease of PTH despite a 
decrease of renal function. This occurred without any change 
in serum levels of phosphate and calcium. This suggests that 
cholecalciferol supplementation may be effective and safe in 
the early-stage CKD patients with hypovitaminosis D.
As already discussed, the inverse relationship between 
PTH and 25-hydroxyvitamin D is well known, and it occurs 
in the earlier stages of CKD, ie, when more chances of 
Table 4 changes of the studied parameters from baseline to 12-
month treatment with oral cholecalciferol (10,000 IU/week)
Patients, n=100 Baseline 12 Months
25-hydroxyvitamin D, ng/ml 12.3±5.9 22.4±8.9***
PTh, pg/ml 134.5±79.8 118±82.2*
serum calcium, mg/dl 9.4±0.5 9.5±0.4
serum phosphate, mg/dl 3.3±0.6 3.4±0.7
serum urea, mg/dl 71.8±24.8 76.9±28.3
egFR, ml/min/1.73 m2 40.3±15.1 37.6±16.9*
serum albumin, g/dl 4.0±0.4 4.1±0.4
hemoglobin, g/dl 12.9±1.6 12.9±1.6
Notes: *P,0.05, ***P,0.001 vs baseline.
Abbreviations: eGFR, estimated glomerular filtration rate; PTH, parathyroid 
hormone.
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1,25-hydroxyvitamin D synthesis happen.11 To confirm, 
studies of ergocalciferol or cholecalciferol supplementation 
have demonstrated PTH reductions (even if quite modest) 
that are more likely to occur in stage 3 CKD, while in stages 
4–5 CKD this beneficial effect was not observed.18–20
The attenuation of secondary hyperparathyroidism by 
ergocalciferol or cholecalciferol was not confirmed in other 
series.21,22
Given that the majority of CKD patients, independently 
on the stage, have a condition of hypovitaminosis D, the 
cholecalciferol administration may safely contribute to ame-
liorate calcium–phosphate abnormalities in CKD. Oral chole-
calciferol at the dosage of 10,000 IU once-a-week should be 
recommended as a regular practice in CKD care management 
even when determinations of 25-hydroxyvitamin D serum 
levels are not feasible. This is true, especially in diabetic, 
elderly, or proteinuric patients.
Major limitation of the study consists in the observational, 
single-center, retrospective design. Conversely, the number 
of patients is quite larger than other published studies, and 
it allows analysis of the different CKD stages too. Although 
the cholecalciferol supplementation was performed with a 
nonrandomized retrospective design, the 12-month follow-up 
was longer than in other studies and may prevent the bias due 
to seasonal variability.
In summary, hypovitaminosis D is very prevalent in 
CKD patients in Italy, and it is similar to other locations. 
PTH serum levels and age, but not renal function, are the 
major correlates of hypovitaminosis D. Implementation of 
renal diets, including low-protein diets, is not associated 
with higher risk of vitamin D depletion. Oral cholecalcif-
erol administration increased 25-hydroxyvitamin D levels 
and mildly reduced PTH serum levels. Oral cholecalciferol 
supplementation should be recommended as a regular 
practice in CKD patients, also when 25-hydroxyvitamin D 
determination is not available or feasible.
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